Status:
ReviewerMember since: 2023
Organization: Dent County Health Center
Improves antibiotic stewardship!
Application Area: Primary Care
"I love having an in house Biofire. It has increased my ability to provide good antibiotic stewardship. Many times patients want an antibiotic and if I can show them a positive viral infection from the Biofire than it helps them to understand. Most importantly they are not given an unnecessary medication and I am not contributing to antibiotic resistance."
Status:
ReviewerMember since: 2023
Organization: Bingham Memorial Hosptial
This product is incredibly easy to use with relatively quick turn around times.
Application Area:Respiratory and G.I. Panel testing
"Large panels for quick diagnosis of respiratory and G.I. pathogens. Smaller labs no longer have to compromise on delivering high quality results in a timely fashion for viral and bacterial pathogens. Truly an amazing product! The only drawback is that some insurance providers have not kept up with the technology and have therefore fallen behind on some reimbursements for syndromic testing."
Traditionally, clinical care of respiratory tract infections is designed around centralized laboratory testing. The BIOFIRE 2.0 EZ Configuration is helping to shift the standard of care to decentralized, point-of-care settings, creating a simplified process with faster results.
Designed for use with the BIOFIRE® FILMARRAY® Respiratory 2.1-EZ Panel (EUA)* in CLIA-waived testing sites, including clinics and physician offices
*This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Manufacturer bioMérieux USA | Available in North America, South Central America
4.9 / 5.0 | 2 reviews